ADMA Biologics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021
January 19, 2022 at 08:31 am EST
Share
ADMA Biologics, Inc. provided revenue guidance for the fourth quarter and full year of 2021. The company expects record fourth quarter 2021 revenues of approximately $26 million, compared to $14 million during the fourth quarter of 2020, reflecting an approximate 86% increase.
For full year 2021, the company expects total revenues of approximately $81 million, compared to $42 million for the full year 2020, reflect a substantial increase of approximately 92% over full year 2020.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA BIOLOGICS, INC. 
